Characterization of nanoparticle-based contrast agents for molecular magnetic resonance imaging

Journal of Nanoparticle Research

Volumn 14, Issue 9, 2012, Pages

  Shan, Liang ^a   Chopra, Arvind ^a   Leung, Kam ^a   Eckelman, William C ^a   Menkens, Anne E ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Characterization; Contrast agent; Molecular imaging; MRI; Nanoparticles

Indexed keywords

ANIMALS; MAGNETIC RESONANCE IMAGING; NANOMAGNETICS; NANOPARTICLES; PHYSICOCHEMICAL PROPERTIES; QUALITY CONTROL;

CHARACTERIZATION OF NANOPARTICLES; CONTRAST AGENT; CONTROL PARAMETERS; MRI CONTRAST AGENTS; NATIONAL INSTITUTES OF HEALTH; ON-LINE INFORMATION; PRECLINICAL STUDIES; SINGLE SET OF PARAMETERS;

MOLECULAR IMAGING;

GADOLINIUM; GADOLINIUM CHELATE; GADOTERIC ACID; IRON OXIDE; LIPOSOME; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE; TETRAXETAN;

ATOMIC ABSORPTION SPECTROMETRY; BINDING AFFINITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAGNETIC FIELD; MASS SPECTROMETRY; MICELLE; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECOMMENDED DRUG DOSE; REVIEW; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84865239066     PISSN: 13880764     EISSN: 1572896X     Source Type: Journal    
DOI: 10.1007/s11051-012-1122-z     Document Type: Review

References (57)

1. Aime S, Caravan P (2009) Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 30:1259-1267
2. Alford R, Ogawa M, Choyke PL, Kobayashi H (2009) Molecular probes for the in vivo imaging of cancer. Mol BioSyst 5:1279-1291
3. Artemov D, Bhujwalla ZM, Bulte JW (2004) Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 5:485-494 (Pubitemid 39654846)
4. Benet LZ (2010) Clearance (nee Rowland) concepts: A downdate and an update. J Pharmacokinet Pharmacodyn 37:529-539
5. Blamire AM (2008) The technology of MRI-The next 10 years? Br J Radiol 81:601-617
6. Brown SC, Palazuelos M, Sharma P, Powers KW, Roberts SM, Grobmyer SR, Moudgil BM (2010) Nanoparticle characterization for cancer nanotechnology and other biological applications. Methods Mol Biol 624:39-65
7. Bulte JW (2009) In vivo MRI cell tracking: Clinical studies. AJR Am J Roentgenol 193:314-325
8. Cheng KT, Menkens A, Bryant S, Sullivan DC (2007) NIH MICAD initiative and guest author program opportunities. J Nucl Med 48:19N
9. Cheng Z, Thorek DL, Tsourkas A (2010) Gadolinium-conjugated dendrimer nanoclusters as a tumor-Targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl 49:346-350
10. Chopra A, Shan L, Eckelman WC, Leung K, Mankens AE (2011) Important parameters to consider for the characterization of PET and SPECT imaging probes. Nucl Med Biol 38:1079-1084
11. Chopra A, Shan L, Eckelman WC, Leung K, Latterner M, Bryant S, Menkens A (2012) Molecular imaging and contrast agent database (MICAD): Evolution and progress. Mol Imaging Biol 14:4-13
12. Cipolla L, Gregori M, So PW (2011) Glycans in magnetic resonance imaging: Determinants of relaxivity to smart agents, and potential applications in biomedicine. Curr Med Chem 18:1002-1018
13. Corsi DM, Platas-Iglesias C, Van Bekkum H, Peters JA (2001) Determination of paramagnetic lanthanide(III) concentrations from bulk magnetic susceptibility shifts in NMR spectra. Magn Reson Chem 39:723-726
14. de la Fuente JM, Grazu V (2012) Nanotechnology: Inorganic nanoparticles vs organic nanoparticles, vol 4. Elsevier, Amsterdam
15. Debbage P, Jaschke W (2008) Molecular imaging with nanoparticles: Giant roles for dwarf actors. Histochem Cell Biol 130:845-875
16. Delikatny EJ,PoptaniH(2005)MRtechniques for in vivo molecular and cellular imaging. Radiol Clin North Am 43:205-220 (Pubitemid 40326569)
17. Di Marco M, Guilbert I, Port M, Robic C, Couvreur P, Dubernet C (2007a) Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. Int J Pharm 331:197-203 (Pubitemid 46216672)
18. Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C (2007b) Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine 2:609-622
19. Eckelman WC, Kilbourn MR, Joyal JL, Labiris R, Valliant JF (2007) Justifying the number of animals for each experiment. Nucl Med Biol 34:229-232 (Pubitemid 46442899)
20. Eckelman WC, Kilbourn MR, Mathis CA (2009) Specific to nonspecific binding in radiopharmaceutical studies: It's not so simple as it seems! Nucl Med Biol 36:235-237
21. Fadeel B, Garcia-Bennett AE (2010) Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev 62:362-374
22. Fox GB, Chin CL, Luo F, Day M, Cox BF (2009) Translational neuroimaging of the CNS: Novel pathways to drug development. Mol Interv 9:302-313
23. Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69:1-9 (Pubitemid 351467152)
24. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE (2007) Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol 2:249-255 (Pubitemid 46739812)
25. Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995-4021 (Pubitemid 40044762)
26. Haun JB, Yoon TJ, Lee H, Weissleder R (2010) Magnetic nanoparticle biosensors. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:291-304
27. Hellman RN (2011) Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 31:310-316
28. Hermann P, Kotek J, Kubicek V, Lukes I (2008) Gadolinium (III) complexes as MRI contrast agents: Ligand design and properties of the complexes. Dalton Trans 21:3027-3047
29. Karmali PP, Simberg D (2011) Interactions of nanoparticles with plasma proteins: Implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 8:343-357
30. Koh TS, Bisdas S, Koh DM, Thng CH (2011) Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI. J Magn Reson Imaging 34:1262-1276
31. Koole R, van Schooneveld MM, Hilhorst J, Castermans K, Cormode DP, Strijkers GJ, Donega CD, Vanmaekelbergh D, Griffioen AW, Nicolay K, Fayad ZA, Meijerink A, Mulder WJM (2008) Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: A new contrast agent platform for multimodality imaging. Bioconjug Chem 19:2471-2479
32. Langley J, Liu W, Jordan EK, Frank JA, Zhao Q (2011) Quantification of SPIO nanoparticles in vivo using the finite perturber method. Magn Reson Med 65:1461-1469
33. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN (2008) Magnetic iron oxide nanoparticles: Synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 108:2064-2110
34. Leung K, Chopra A, Shan L, Eckelman WC, Menkens A (2012) Essential parameters to consider for the characterization of optical imaging probes. Nanomed 7:1101-1107
35. Lodhia J, Mandarano G, Ferris N, Eu P, Cowell S (2010) Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI. Biomed Imaging Interv J 6:e12
36. Lowe MP (2004) Activated MR contrast agents. Curr Pharm Biotechnol 5:519-528 (Pubitemid 39654849)
37. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser B, Reubi JC, Maecke HR (2005) Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-Targeting drugs. J Nucl Med 46:823-830
38. Makowski MR, Wiethoff AJ, Jansen CH, Botnar RM (2009) Molecular imaging with targeted contrast agents. Top Magn Reson Imaging 20:247-259
39. Mankoff DA, O'Sullivan F, Barlow WE, Krohn KA (2007) Molecular imaging research in the outcomes era: Measuring outcomes for individualized cancer therapy. Acad Radiol 14:398-405 (Pubitemid 46401412)
40. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17:545-580 (Pubitemid 36307540)
41. Morcos SK (2008) Extracellular gadolinium contrast agents: Differences in stability. Eur J Radiol 66:175-179
42. Pakzad F, Ell PJ, Carrio I (2005) Molecular imaging in animal models of disease-every little detail counts! Eur J Nucl Med Mol Imaging 32:899-900 (Pubitemid 41205659)
43. Ptak K, Farrell D, Panaro NJ, Grodzinski P, Barker AD (2010) The NCI alliance for nanotechnology in cancer: Achievement and path forward. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:450-460
44. Rosenblum LT, Kosaka N, Mitsunaga M, Choyke PL, Kobayashi H (2010) In vivo molecular imaging using nanomaterials: General in vivo characteristics of nano-sized reagents and applications for cancer diagnosis. Mol Membr Biol 27:274-285
45. Sayes CM, Warheit DB (2009) Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:660-670
46. Schladt TD, Schneider K, Schild H, TremelW(2011) Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 40:6315-6343
47. Schrand AM, Rahman MF, Hussain SM, Schlager JJ, Smith DA, Syed AF (2010) Metal-based nanoparticles and their toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:544-568
48. Shah B, Anderson SW, Scalera J, Jara H, Soto JA (2011) Quantitative MR imaging: Physical principles and sequence design in abdominal imaging. Radiographics 31:867-880
49. Shan L, Wang S, Sridhar R, Bhujwalla ZM, Wang PC (2007) Dual probe with fluorescent and magnetic properties for imaging solid tumor xenografts. Mol Imaging 6:85-95 (Pubitemid 46955992)
50. Sherry AD, Caravan P, Lenkinski RE (2009) Primer on gadolinium chemistry. J Magn Reson Imaging 30:1240-1248
51. Shiraishi K, Kawano K, Minowa T, Maitani Y, Yokoyama M (2009) Preparation and in vivo imaging of PEG-poly(Llysine)-based polymeric micelle MRI contrast agents. J Control Release 136:14-20
52. Shiraishi K, Kawano K, Maitani Y, Yokoyama M (2010) Polyion complex micelle MRI contrast agents from poly(ethylene glycol)-b-poly(L-lysine) block copolymers having Gd-DOTA; preparations and their control of T(1)-relaxivities and blood circulation characteristics. J Control Release 148:160-167
53. Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J (2011) Shapespecific polymeric nanomedicine: Emerging opportunities and challenges. Exp Biol Med (Maywood) 236:20-29
54. Tei L, Mazooz G, Shellef Y, Avni R, Vandoorne K, Barge A, Kalchenko V, Dewhirst MW, Chaabane L, Miragoli L, Longo D, Neeman M, Aime S (2010) Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity. Contrast Media Mol Imaging 5:213-222
55. Tinkle SS (2010) Maximizing safe design of engineered nanomaterials: The NIH and NIEHS research perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2:88-98
56. Weissleder R (2006) Molecular imaging in cancer. Science 312:1168-1171 (Pubitemid 43801133)
57. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J (1989) Superparamagnetic iron oxide: Pharmacokinetics and toxicity. AJR Am J Roentgenol 152:167-173 (Pubitemid 19024086)